Bradycardia News and Research

RSS

Bradycardia, ("heart slowness"), as applied to adult medicine, is defined as a resting heart rate of under 60 beats per minute, though it is seldom symptomatic until the rate drops below 50 beat/min.

Egalet announces net revenues of $1.9 million for 2014

Egalet Corporation today reported financial results for the year ended December 31, 2014.

16 Mar 2015

Organ-on-a-chip could replace use of animals to test drugs for safety and efficacy

When University of California, Berkeley, bioengineers say they are holding their hearts in the palms of their hands, they are not talking about emotional vulnerability.

12 Mar 2015

Amgen announces phase 3 ivabradine data for treatment of chronic HF

Amgen (NASDAQ: AMGN) today announced data from the Phase 3 SHIFT (Systolic Heart failure treatment with the If inhibitor ivabradine Trial) study evaluating ivabradine in patients with chronic heart failure (HF) were presented at the 18th Annual Scientific Meeting of the Heart Failure Society of America (HFSA) in Las Vegas.

15 Sep 2014

Huntington Memorial Hospital patient implanted with tiny, leadless cardiac pacemaker

A Huntington Memorial Hospital patient has become the first patient in the San Gabriel Valley to be implanted with a tiny, leadless cardiac pacemaker. Developed for patients with bradycardia - a heart rate that is too slow - the Nanostim device is designed to be placed directly in a patient's heart without the visible lump, scar and insulated wires (called leads) required for conventional pacemakers.

23 Jun 2014

Leadless pacemaker technology shows promising performance after 12 months

Vivek Reddy, MD, Director of Arrhythmia Services for The Mount Sinai Hospital, reported his promising12-month follow-up data showing the world's first leadless pacemaker is demonstrating overall device performance comparable to conventional pacemakers. Dr. Reddy presented the one-year LEADLESS study data findings during his late-breaking clinical trial presentation on May 9 at Heart Rhythm 2014, the Heart Rhythm Society's 35th Annual Scientific Sessions in San Francisco, CA.

12 May 2014

Novartis presents Phase III results of Signifor LAR therapy in patients with acromegaly

Novartis today presented results from a pivotal Phase III trial of investigational therapy Signifor® LAR (pasireotide LAR; SOM230) in patients with acromegaly for whom current standard of care provides inadequate disease control.

6 May 2014

Richard M. Ross Heart Hospital docs implanted smallest heart pacemaker in Columbus woman

It's about the size of a large vitamin pill and, for the first time in Ohio, the smallest heart pacemaker available is being tested at The Ohio State University Wexner Medical Center.

From Medtronic 2 May 2014

Genmab/GSK receive FDA sBLA approval for Arzerra in combination with chlorambucil for treatment of CLL

GlaxoSmithKline plc and Genmab A/S announced today that the U.S. Food and Drug Administration (FDA) has approved a Supplemental Biologic License Application (sBLA) for the use of Arzerra® (ofatumumab), a CD20-directed cytolytic monoclonal antibody, in combination with chlorambucil for the treatment of previously untreated patients with chronic lymphocytic leukaemia (CLL) for whom fludarabine-based therapy is considered inappropriate.

21 Apr 2014

Report describes cardiopulmonary arrest in infant following cyclopentolate eyedrops

Eyedrops administered to infants as part of routine outpatient retinopathy of prematurity (ROP) screening can have life-threatening consequences. A case report published in the current issue of the Journal of the American Association for Pediatric Ophthalmology and Strabismus (AAPOS) describes cardiopulmonary arrest in a 27-week-old infant following administration of three sets of cyclopentolate 0.2%/phenylephrine 1% (Cyclomydril) eyedrops.

3 Apr 2014

St. Jude Medical announces first enrollments in LEADLESS Pacemaker Observational Study

St. Jude Medical, Inc., a global medical device company, today announced the first enrollments in the company’s LEADLESS Pacemaker Observational Study evaluating the Nanostim leadless pacing technology. The Nanostim pacemaker received CE Mark in 2013, and post-approval implants have occurred in the UK, Germany, Italy, Czech Republic, France, Spain, and the Netherlands.

19 Mar 2014

Pierre Fabre Dermatologie receives FDA marketing authorization for pediatric drug Hemangeol

Pierre Fabre Dermatologie has obtained marketing authorization from the FDA for the pediatric drug Hemangeol (propranolol hydrochloride), which is the first and only approved treatment for "proliferating infantile hemangioma requiring systemic therapy".

18 Mar 2014

Discovery Laboratories reports net loss of $11.7 million for fourth quarter 2013

Discovery Laboratories, Inc., a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced financial results for the fourth quarter ended December 31, 2013, as well as recent business updates.

13 Mar 2014

Clonidine before surgery may control post-surgical pain and child's anxiety

Managing a child's pain and distress after surgery is an essential part of recovery. However, using strong painkilling medications post-surgery can put kids at risk for side effects and other complications.

31 Jan 2014

London hospital implants world’s first leadless pacemaker

St. Jude Medical, Inc., a global medical device company, today announced the first post-approval implant of the Nanostim™ leadless pacemaker in the U.K. The world's first retrievable leadless pacemaker was implanted at St. Bartholomew's Hospital in London by Professor Richard Schilling.

27 Jan 2014

BMC reduced audible alarms as a way to combat alarm fatigue, improve patient safety

Boston Medical Center (BMC) successfully reduced audible alarms as a way to combat alarm fatigue and improve patient safety. The hospital, one of two in the country that spearheaded this issue, implemented a novel cost-effective approach during a six-week pilot program that resulted in a drastic drop in audible alarms.

16 Jan 2014

iRhythm Technologies’ ZIO Service detects more cardiac arrhythmias than Holter monitor

iRhythm Technologies, a healthcare information services company, today announced that a prospective study by Scripps Translational Science Institute (STSI) has found that use of the company's ZIO Service significantly increased detection of cardiac arrhythmias, compared to use of the traditional Holter monitor.

3 Jan 2014

Forest Laboratories to acquire exclusive rights in the U.S. for Saphris sublingual tablets

Forest Laboratories Holdings Limited, a wholly owned subsidiary of Forest Laboratories, Inc. today announced that the company is acquiring exclusive rights in the United States for Saphris (asenapine) sublingual tablets, a treatment for adult patients with schizophrenia or acute bipolar mania, from Merck Sharp & Dohme B.V., a wholly owned subsidiary of Merck & Co., Inc.

3 Dec 2013

Discovery Labs submits IND application to start AEROSURF phase 2 clinical program

Discovery Laboratories, Inc., a specialty biotechnology company dedicated to advancing a new standard of respiratory critical care, today announced that it has submitted an investigational new drug application to the U.S. Food and Drug Administration to initiate its AEROSURF phase 2 clinical program.

17 Oct 2013

St. Jude Medical completes Nanostim acquisition; leadless pacemaker receives CE Mark approval

St. Jude Medical, Inc., a global medical device company, today announced the completion of its acquisition of Nanostim, Inc., a privately-owned developer of miniaturized, leadless pacemakers.

15 Oct 2013

FDA approves Discovery Lab’s updated product specifications for SURFAXIN lucinactant

Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced the U.S. Food and Drug Administration (FDA) has agreed to the Company's updated product specifications for SURFAXIN® (lucinactant) Intratracheal Suspension which was approved for the prevention of respiratory distress syndrome (RDS) in premature infants at high risk for RDS.

5 Oct 2013